

Journal of Andrology, Vol 12, Issue 5 315-322, Copyright © 1991 by The American Society of Andrology


JOURNAL ARTICLE

4-MAPC, a 5 alpha-reductase inhibitor, reduces rat ventral prostate weight, DNA, and prostatein concentrations

H. F. Ghusn, T. C. Shao, M. Klima and G. R. Cunningham
Department of Veterans Affairs Medical Center, Houston, Texas.

Several compounds, such as 4-MAPC (4-methyl-3-oxo-4-aza-5 alpha-pregnane-20-carboxylate), that inhibit conversion of testosterone (T) to dihydrotestosterone (DHT) by 5 alpha-reductase have been demonstrated to reduce prostate size in rats and dogs. The current studies were undertaken to determine if this effect is due to a reduction in cell number, in epithelial cell synthetic activity, or both. Eight-week-old intact rats were treated daily for 14 days with sesame seed oil, 4-MAPC (10 mg/kg), 4-MAPC + testosterone propionate (TP, 1 mg/kg), or 4-MAPC + TP (3 mg/kg). Rats were killed 24 hours after the last injection. In the animals treated only with 4-MAPC, ventral prostate weight was reduced 37%, but the 14% reduction in total DNA was not significant. The mean intraprostatic concentration of prostatein, a major secretory protein, was reduced 45% (P less than 0.05). The 3 mg/kg dose of TP increased ventral prostate weight, prostatein concentrations, and acid phosphatase activity, even though DNA/ventral prostate was similar to that in control animals. These observations indicate that the reduction in ventral prostate weight in adult rats is due in part to a reduction in cell number, but the primary effect was due to a reduction in synthetic activity, and possibly atrophy of the epithelial cells. Furthermore, TP in pharmacologic doses increased ventral prostate weight and synthetic activity without increasing DNA.

This article has been cited by other articles:



Endocrinology

[HOME](#)

A. S. Wright, R. C. Douglas, L. N. Thomas, C. B. Lazier, and R. S. Rittmaster

Androgen-Induced Regrowth in the Castrated Rat Ventral Prostate: Role of 5{alpha}-Reductase

Endocrinology, October 1, 1999; 140(10): 4509 - 4515.

[\[Abstract\]](#) [\[Full Text\]](#)

This Article

- ▶ [Full Text \(PDF\)](#)
- ▶ [Alert me when this article is cited](#)
- ▶ [Alert me if a correction is posted](#)

Services

- ▶ [Similar articles in this journal](#)
- ▶ [Similar articles in PubMed](#)
- ▶ [Alert me to new issues of the journal](#)
- ▶ [Download to citation manager](#)

Citing Articles

- ▶ [Citing Articles via HighWire](#)
- ▶ [Citing Articles via Google Scholar](#)

Google Scholar

- ▶ [Articles by Ghusn, H. F.](#)
- ▶ [Articles by Cunningham, G. R.](#)
- ▶ [Search for Related Content](#)

PubMed

- ▶ [PubMed Citation](#)
- ▶ [Articles by Ghusn, H. F.](#)
- ▶ [Articles by Cunningham, G. R.](#)

